Endothelial dysfunction in patients with chronic kidney disease: 616-06:616.61

Abstract

Summary. Morphological changes in the vascular wall during endothelial dysfunction (ED) are clinically significant in cardiovascular diseases. These changes result in vascular hyperpermeability, vasoconstriction, impaired microcirculation, vascular thrombophilia, multiple microthrombi, and the progression of atherosclerosis, which increases the risk of adverse cardiovascular outcomes. ED affects both large vessels
and the microcirculatory system. If a patient has an impaired renal function, the severity of ED increases. Chronic kidney disease is an independent risk factor for ischemic heart disease and adverse outcomes in patients with cardiovascular diseases. Therefore, careful and early diagnosis of possible complications is required in comorbid patients.

For citation: Zolotovskaya I.A., Ramodina M.E. Endothelial dysfunction in patients with chronic kidney disease. Tromboz, gemostaz i reologiya.
2025;(2):44–52. (In Russ.).

References

1. Panina I. Yu., Rumyantsev A. Sh., Menshutina M.A. et al. Specific functions of the endothelium in chronic kidney disease. Literature review and personal data. Nefrologiya. 2007;11(4):28–46. (In Russ.).
2. Margieva T.V., Sergeeva T.V. The involvement of endothelial dysfunction markers in the pathogenesis of chronic glomerulonephritis. Voprosy sovremennoj pediatrii. 2006;5(3):22–30. (In Russ.).
3. Uttara B., Singh A.V., Zamboni P., Mahajan R.T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009;7(1):65–74. DOI: 10.2174/157015909787602823.
4. Sosa V., Moliné T., Somoza R. et al. Oxidative stress and cancer: an overview. Ageing Res Rev. 2013;12(1):376–90. DOI: 10.1016/j. arr.2012.10.004.
5. Massy Z.A., Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol. 2002;15(4):336–41.
6. Park H.S., Chun J.N., Jung H.Y. et al. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res. 2006;72(3):447–55. DOI: 10.1016/j.cardiores.2006.09.012.
7. Durand M.J., Gutterman D.D. Diversity in mechanisms of endothelium-dependent vasodilation in health and disease. Microcirculation. 2013;20(3):239–47. DOI: 10.1111/micc.12040.
8. Martynov A.I., Avetyak N.G., Akatova E.V. et al. Endothelial dysfunction and methods for its diagnostics. Rossijskij kardiologicheskij zhurnal. 2005;10(4):94–8. (In Russ.).
9. Mittal M., Siddiqui M.R., Tran K. et al. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126–67. DOI: 10.1089/ars.2012.5149.
10. Potenza M.A., Gagliardi S., Nacci C. et al. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009;16(1):94–112. DOI: 10.2174/092986709787002853.
11. Wolin M.S., Gupte S.A., Neo B.H. et al. Oxidant-redox regulation of pulmonary vascular responses to hypoxia and nitric oxidecGMP signaling. Cardiol Rev. 2010;18(2):89–93. DOI: 10.1097/CRD.0b013e3181c9f088.
12. Liaudet L., Vassalli G., Pacher P. Role of peroxynitrite in the redox regulation of cell signal transduction pathways. Front Biosci (Landmark Ed). 2009;14(12):4809–14. DOI: 10.2741/3569.
13. Dharmashankar K., Widlansky M.E. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep.2010;12(6):448–55. DOI: 10.1007/s11906-010-0150-2.
14. Piccirillo F., Mastroberardino S., Nusca A. et al. Novel antidiabeticagents and their effects on lipid profile: a single shot for several cardiovascular targets. Int J Mol Sci. 2023;24(12):10164. DOI: 10.3390/ijms241210164.
15. Premji R., Nylen E.S., Naser N. et al. Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome. Metab Syndr Relat Disord. 2022;20(6):321–8. DOI: 10.1089/met.2022.0004.
16. Bacon P.A. Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects. Curr Opin Rheumatol.2005;17(1):49–55. DOI:10.1097/01.bor.0000149084.16639.b0.
17. Kiseleva A.V., Leskova A.V., SkvortsovV.V. Kidney pathology in COVID-19 patients. Lechashchij vrach. 2022;25(9):19–23. (In Russ.). DOI: 10.51793/OS.2022.25.9.003.
18. Fadeev G.A., Fatykhov R.G., Tsibulkin N.A. et al. Inflammatory mechanisms in genesis of atherosclerosis.Vestnik sovremennoj klinicheskoj mediciny. 2020;13(6):62–7. (In Russ.). DOI: 10.20969/VSKM.2020.13(6).62-67.
19. Zabolotskikh I.B., Sinkov S.V., Bulanov A.Yu. et al. Perioperative management of patients with hemostatic system disorders. Methodological recommendations of the All-Russian public organization “Federation of Anesthesiologists and Reanimatologists” and the National Association of Specialists in Thrombosis, Clinical Hemostasiology and Hemorheology. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2024;(1):7–46. (In Russ). DOI: 10.21320/1818-474X-2024-1-7-46.
20. Vorobyeva E.N., Vorobyev R.I., Sharlaeva E.A. et al. Endothelial dysfunction in cardiovascular diseases: risk factors, methods of diagnostic, and correction. Acta Biologica Sibirica. 2016;2(1):21–40. (In Russ.).
21. Fatenkov O.V., Simerzin V.V., Gagloeva I.V. et al. Endothelial dysfunction as predictor of subclinical and manifest atherosclerosis. Nauka i innovacii v medicine.2018;(3):39–46. (In Russ.).
22. Wilson J.M., Ferguson J.J. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. Clin Cardiol. 1999;22(11):687–98. DOI: 10.1002/clc.4960221103.
23. Programmed hemodialysis. Nefrologiya i dializ. 2015;17(3):312–26. (In Russ.).
24. Yau J.W., Teoh H., Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15:130. DOI: 10.1186/s12872-015-0124-z.
25. Baaten C.C.F.M.J., Schröer J.R., Floege J. et al. Platelet abnormalities in CKD and their implications for antiplatelet therapy. Clin J Am Soc Nephrol. 2022;17(1):155–70. DOI: 10.2215/CJN.04100321.
26. Melnнk A.A. Hemostatic system and its regulation in disorders of renal function. Pochki. 2016;(3):57–75. (In Russ.). DOI: 10.22141/2307-1257.3.17.2016.76541.
27. Addi T., Dou L., Burtey S. Tryptophan-derived uremic toxins and thrombosis in chronic kidney disease. Toxins (Basel). 2018;10(10):412. DOI: 10.3390/toxins10100412.
28. Fryc J., Naumnik B. Thrombolome and its emerging role in chronic kidney diseases. Toxins (Basel). 2021;13(3):223. DOI: 10.3390/toxins13030223.
29. Jourde-Chiche N., Fakhouri F., Dou L. et al. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol. 2019;15(2):87–108. DOI: 10.1038/s41581-018-0098-z.
30. Kamenshchikov N.O., Tyo M.A., Podoksenov Y.K. et al. Perioperative nitric oxide conditioning to prevent acute kidney injury during cardiac surgery in patients with chronic kidney disease: interim results of the randomised controlled DEFENDER trial. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2024;(4):127–38. (In Russ). DOI: 10.21320/1818-474X-2024-4-127-138.
31. Jankauskas S.S., Andrianova N.V., Alieva I.B. et al. Dysfunction of kidney endothelium after ischemia/reperfusion and its prevention using by mitochondria-targeted antioxidant. Biohimiya. 2017;82(1):51–63. (In Russ.).
32. Aitbaev K.A., Murkamilov I.T., Fomin V.V. Arterial stiffness as a new risk factor for the progression of nephropathy. Vestnik Dagestanskoj gosudarstvennoj medicinskoj akademii. 2017;(3):64–71. (In Russ.).
33. Bolton С.Н., Downs L.G., Victory J.G. et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and proinflammatory cytokines. Nephrol Dial Transplant. 2001;16(6):1189–97. DOI: 10.1093/ndt/16.6.1189.
34. Nangaku M., Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res. 2008;31(2):175–84. DOI: 10.1291/hypres.31.175.
35. Kurapova M.V., Nizyamova A.R., Romasheva E.P., Davydkin I.L. The feature basal blood flow in patient with chronic kidney disease. Mezhdunarodnyj nauchno-issledovatel’skij zhurnal. 2014;(3–4):80–1. (In Russ.).
36. Golovchenko Yu.I., Treshchinskaya M.A. Review of modern concepts of endothelial dysfunction. Consilium medicum Ukraina. 2010;(11):38–40. (In Russ.).
37. Chizh K.A. “New” risk factor in chronic kidney disease. Kardiologiya v Belarusi. 2020;12(S1–1):129–38. (In Russ.).
38. Dzheentaev K.Sh., Kaliyev R.R. Pulmonary hypertension in patients on chronic long-term hemodialysis. Klinicheskaya medicina Kazahstana.2014;(S1–1):62–4. (In Russ.).
39. Borodulina E.O., Karpunin S.A., Shutov A.M. Pulmonary hypertension in dialysis patients. Klinicheskaya nefrologiya. 2015;(1):19–22. (In Russ.).
40. Pushkina A.V., Pushkin I.A., Ternovoy S.K. Effect of phosphoruscalcium metabolism (PCM) disorders in patients on programmed hemodialysis (HD) on changes in bone mineral density (BMD). Nefrologiya i dializ. 2015;17(3):312. (In Russ.).
41. Chronic kidney disease. Nefrologiya i dializ. 2018;20(4):416–38. (In Russ.). DOI: 10.28996/2618-9801-2018-4-416-467.
42. Carracedo J., Alique M., Vida C. et al. Mechanisms of cardiovascular disorders in patients with chronic kidney disease: a process related to accelerated senescence. Front Cell Dev Biol. 2020;8:185. DOI: 10.3389/fcell.2020.00185.
43. Valencia I., Lumpuy-Castillo J., Magalhaes G. et al. Mechanismsof endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus. Cardiovasc Diabetol. 2024;23(1):75. DOI: 10.1186/s12933-023-02097-8.
44. Ivey M.E., Osman N., Little P.J. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis. 2008;199(2):237–47. DOI: 10.1016/j.atherosclerosis.2008.03.006.
45. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta. 2010;411(19–20):1412–20. DOI: 10.1016/j.cca.2010.06.019.
46. Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23. DOI: 10.1016/S0140-6736(05)17741-1.
47. Zeltyn-Abramov E.M., Frolova N.F. Hypertension and chronic kidney disease: from initial to advanced stages. Diagnostic and therapeutic strategies. Part 1. Hypertension in chronic kidney disease 1–4 stages. Nefrologiya i dializ. 2020;22(2):221–36. (In Russ.). DOI: 10.28996/2618-9801-2020-2-221-236.
48. Goel N., Jain D., Haddad D.B., Shanbhogue D. Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences. J Stroke. 2020;22(3):306–16. DOI: 10.5853/jos.2020.01886.